Analyst Expectations For Collegium Pharmaceutical's Future

During the last three months, 4 analysts shared their evaluations of Collegium Pharmaceutical COLL, revealing diverse outlooks from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $38.5, a high estimate of $40.00, and a low estimate of $37.00. Observing a 19.08% increase, the current average has risen from the previous average price target of $32.33.

Understanding Analyst Ratings: A Comprehensive Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Collegium Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Collegium Pharmaceutical. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Collegium Pharmaceutical compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Collegium Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into Collegium Pharmaceutical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Collegium Pharmaceutical analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Collegium Pharmaceutical's Financial Performance

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Collegium Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 7.63%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Collegium Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of 15.09%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Collegium Pharmaceutical's ROE excels beyond industry benchmarks, reaching 10.87%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Collegium Pharmaceutical's ROA excels beyond industry benchmarks, reaching 1.73%. This signifies efficient management of assets and strong financial health.

Debt Management: Collegium Pharmaceutical's debt-to-equity ratio is notably higher than the industry average. With a ratio of 4.02, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

The Basics of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.